This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Israel Makov Appointed Chairman Of Sun Pharma Board

Stocks in this article: SUN

MUMBAI, May 29, 2012 /PRNewswire/ --

The Board of Directors of Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) met today and announced appointment of Mr Israel Makov as Chairman of the Board.

Mr. Makov is the former President and CEO of Teva Pharmaceutical Industries Ltd (2002-2007). He is among Israel's most respected corporate leaders, and is widely credited with Teva's emergence as a global company and a world leader in generic pharmaceuticals.

Speaking on the induction, Mr Dilip Shanghvi, Managing Director of Sun Pharma said "I welcome Mr Makov on behalf of the entire Board and the larger Sun Pharma team.  He is an exceptional leader with deep knowledge and experience in globalizing businesses successfully.  As Sun Pharma continues to rapidly expand its presence worldwide, I am sure that we will benefit immensely from his experience."

On his appointment, Mr Makov said, "I am happy to accept the position of Chairman of the Board.  Sun Pharma is an exciting company poised for substantial global expansion and I look forward to working together with Dilip and his team in realizing their visionary goals."

Profile of Mr Israel Makov

Mr Makov is the former President and CEO of Teva Pharmaceutical Industries Ltd.  He joined Teva in 1995 and led the company's global expansion, managing over 12 acquisitions - two of which were the largest M&A deals in the Israeli history at the time.  Under Mr Makov's leadership, Teva became the undisputed global leader in generic pharmaceutical industry and a global leader in the treatment of Multiple sclerosis.  Prior to joining Teva in 1995, Mr. Makov led a number of companies in various industries, and founded Israel's first biotech company, Interpharm which went public in the US as the first Israeli company in R&D stage.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs